PRECISION AQ™

Investor Relations Monthly Newsletter

May 2025

From the desk of
Hannah Deresiewicz

As we navigated through the month of April, I wanted to take a moment to address the recent volatility in the biotech market. It's no secret that the past few weeks have been challenging, with market gyrations driven by various factors, including FDA leadership changes, policy fluctuations and economic uncertainties.

That said, I firmly believe that these "April showers" will (eventually!) bring "May flowers."

Despite the turbulence, our industry remains resilient and full of potential. The biotech sector has always been a beacon of innovation, and even in the face of adversity, we continue to make strides in groundbreaking research and development. The recent market conditions, while unsettling, also present opportunities for growth and adaptation.

One of the key strengths of our industry is its ability to pivot and innovate. The challenges we face today are not insurmountable; rather, they are catalysts for us to refine our strategies and emerge stronger. The current environment encourages us to be more thoughtful in how we engage. By creatively implementing impactful messaging, which articulates the many ways we've built our companies to be resilient and derisked across key clinical, regulatory and commercial dimensions, and by targeting it to the right audiences, we have the highest potential to navigate these challenges successfully, and ensure our clients are best positioned to deliver value to key stakeholders.

As we look ahead, I am optimistic about the future. The biotech industry has a history of overcoming obstacles and emerging stronger. The "showers" we are experiencing now will undoubtedly lead to a period of growth and prosperity. Our commitment to advancing healthcare and improving lives remains unwavering, and we are excited about the opportunities that lie ahead.

Thank you for your continued trust and support. Together, we will turn these challenges into opportunities and continue to thrive as we look forward to welcoming May flowers!

Hannah

Client Shoutout

argenx

Congratulations to Precision AQ client, **argenx,** on receiving **FDA approval for a new option for patients to self-inject VYVGART® Hytrulo** with a prefilled syringe (efgartigimod alfa and hyaluronidase-qvfc) for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor antibody positive and adult patients with chronic inflammatory demyelinating polyneuropathy.

FDA APPROVED

Self-injection provides gMG and CIDP patients with flexibility for when and where to receive treatment – at home, while 'on the go' or in a healthcare setting. VYVGART, the first-in-class FcRn blocker, now offers three administration options.

Company Spotlight

EYEPOINT®

Nowhere are green shoots of optimism more prevalent than at Precision AQ client company, **EyePoint**, where all eyes are on the **fast-approaching completion of enrollment in the pivotal Phase 3 clinical development program** for their lead product candidate, DURAVYU™, as a treatment for wet age-related macular degeneration (wAMD).

Wet age-related macular degeneration is a serious eye condition that occurs when abnormal blood vessels grow under the retina, leading to vision loss. According to the U.S. Center for Disease Control, an estimated 19.8 million (12.6%) Americans aged 40 and older were living with age-related macular degeneration (AMD) in 2019. DURAVYU presents a compelling and strategically de-risked opportunity in wet AMD.

First, DURAVYU is a **clinically validated, differentiated, and potentially best-in-class sustained release TKI.** DURAVYU's receptor-level inhibition of VEGF, including all isoforms of VEGF, offers broader and possibly more durable disease control compared to ligand-only therapeutics. Also, by targeting PDGF receptors, DURAVYU may help reduce fibrosis, a key driver of long-term vision loss.

Next, DURAVYU has a **clean safety profile** with no DURAVYU-related ocular or systemic SAEs across multiple diseases and clinical trials. DURAVYU's efficacy is supported by its Phase 1 and 2 datasets, which are **the most robust investigational datasets in wet AMD** amongst all sustained delivery programs.

EyePoint's de-risked Phase 3 program was **developed in direct alignment with the FDA** and is strategically designed to enhance the probability of regulatory and commercial success.

Finally, DURAVYU has the potential to **address a large unmet need in an established multi-billion dollar market opportunity** where there remains a real need for safe, durable, longer-acting treatments.

It's an exciting time at EyePoint and we are keeping their progress in our sights as we look forward to the completion of the Phase 3 clinical trials and **await what we expect will be outstanding clinical results next year.**

Client Corporate Access

ESPERION

AQ client, Esperion, hosted a successful R&D Day at the Nasdaq MarketSite where they unveiled their promising research supporting lead development candidates for the treatment of Primary Sclerosing Cholangitis (PSC), including ESP-1336.

The event featured KOL discussion, patient advocacy experts and patient videos along with an engaging Q&A session with analysts and investors. In case you missed it, the replay of this dynamic event is available **here**.

Esperion has exciting opportunities ahead and we look forward to the IND sumbission for ESP-1336 and the Company's continued success!

Street Moves
People on the Move

Buyside

Amy Liu
Joined Avidity Partners Management from Mubadala Capital

Nathaniel Tracer
Joined Passaic Capital from Ghost Tree Capital

Matt Cohen
Joined Vida Ventures from J.P. Morgan Asset Management

Brian Goodman
Joined Vida Ventures from MPM Capital

Isai Peimer
Joined Balyasny Asset Management from Surveyor Capital

Steven Breazzano
Left Deep Track Capital to join Novartis as Director, Therapeutic Area Strategy (Cardio, Renal, Metabolic)

Anthony Arceci
Left 5AM Ventures
Next steps TBD

Sell-side Analysts

Chris Shibutani
Left Goldman Sachs to join Bristol Myers Squibb as Chief of Strategy

Joe Catanzaro
Left Piper Sandler.
Next steps TBD

Danielle Brill
Officially joined Truist Securities from Raymond James Financial

Balaji Prasad
Left Barclays to join Alvotech as Chief Strategy Officer

Elemer Piros, Brandon Folkes
Joined H.C. Wainwright, both were previously research analysts at Rodman and Renshaw

Ed Arce, Ed White, Oren Livnat
Left H.C. Wainwright.
Next steps TBD

Brad Canino Benjamin Burnett
Left Stifel.
Next steps TBD

Banking

Arun Master
Left UBS.
Next steps TBD

MEET US IN MANHATTAN
FOR OUR ANNUAL SUMMER
COCKTAIL PARTY

Wednesday, June 4TH 2025
5:30-7:30PM ET

LOCATED IN **THE BROADWAY LOUNGE** AT
The Marriott Marquis Hotel
1535 Broadway, New York, NY

RSVP to Maria DiMartinis,
maria.dimartinis@precisionaq.com

PRECISION AQ™ | PRECISION MEDICINE GROUP®

Breaking News
The Precision AQ PR Way

CereVasc, a clinical stage medical device company, could be the next big MedTech success story according to *Mass Device's Device Talks*.

In a recent podcast episode, President and CEO of CereVasc, Daniel Levangie, sat down with "Device Talks" to discuss all things CereVasc and their novel eShunt System for the treatment of Normal Pressure Hydrocephalus. The eShunt System has **FDA breakthrough device designation**, and just received **its second breakthrough designation for pediatrics**. CereVasc's pivotal study, STRIDE, is actively recruiting across the United States as well as in South America.

Initial results from the US pilot study showed promising data; At the 90-day Primary Endpoint, no (0%) Serious Adverse Events related to the study device or procedure, and no (0%) Unanticipated Adverse Device Effects were reported. Additionally, 97% (29/30) of patients treated demonstrated improvement in the clinical symptoms of NPH.

> *"We are tremendously encouraged by these outstanding preliminary safety and efficacy results. These results support our belief that an endovascular, minimally invasive treatment approach could provide significant safety and efficacy benefits, allowing a greater number of patients with this neurodegenerative disorder to receive treatment."*
>
> **Dan Levangie**
> Chairman & CEO
> CereVasc, Inc.

Access to Perspectives

PRECISION MEDICINE GROUP

Harpreet Singh, MD
Chief Medical Officer
Precision for Medicine

Dr. Harpreet Singh is an industry-leading medical Oncologist and former **Division Director in FDA's Oncology Center of Excellence, where she presided over dozens of approvals for solid tumors and rare diseases**.

Here's her perspective on recent changes at the FDA:

Strong Science Will Continue to Prevail:
FDA is responsible for protecting and advancing public health by ensuring the safety, efficacy, and security of medical products, and by helping speed innovations that **accelerate drug development**. This means that, no matter who's leading the Agency or how much is changing within the Agency, there will always be **appetite for novel science for patients with high unmet need**.

For companies that are able to demonstrate strong science and high-quality data – especially those leveraging novel modalities, going after new targets, or exploring new approaches to administering medicines (IV to oral, for example) – we fully expect clinical development will continue to be regulated as it always has been, with no major interruptions.

Communicate Often and Early:
To minimize interruptions or the risk of miscommunication, it's important to stay in regular contact with the FDA from the earliest stages of development. We recommend each company get to know the individual decision-makers – including the Division Director – who will one day review their drug, so there can be regular conversation and input as programs advance through development.

Interested in speaking with Dr. Singh directly? She'll be in Chicago during ASCO (**May 31-June 2**) and would be happy to connect 1x1 to discuss her perspectives on your ongoing clinical trials and opportunities to optimize and expedite development. Please [click here] to schedule a meeting.

Dr. Singh also hosted a panel at AACR, which explored multi-regional clinical trials in oncology, including regulatory complexities, logistical coordination across multiple regions, and cultural differences that may affect patient recruitment and retention.

Access to the Best & Brightest

PRECISION MEDICINE GROUP

Words of Wisdom
FROM THE TOP

Below is an excerpt from a recent interview with our **EVP, Hannah Deresiewicz** and **Margaret Keegan, CEO of Precision Medicine Group**.

Hannah: It's no secret we're living through a particularly volatile moment in the market, both due to macro factors and industry-specific dynamics. How do you advise that our clients manage through this?

Margaret Keegan: No question, the market is extremely challenging right now, but we've seen this before — like in 2008 and COVID. What we learned from those events is that the fundamentals of our industry are very strong. We have an increasingly aging population and, at the same time, we have so many unmet needs, particularly in areas like oncology, immunology and rare disease.

This means that biotech funding will come back for our clients and for those companies developing strong potential treatments that we need. In the short term, we are advising our clients to focus on spending very wisely — getting the best advice and working with real experts who can help them navigate the current market and industry challenges, while accelerating the delivery of their new drugs to market.

Hannah: In what ways do you think that we, as Precision, can be that advisor and really make the biggest impact for our clients shepherding them through these challenging times?

Margaret Keegan: I've been at Precision for just over six months and the thing that resonates with me most is the passion our employees have at Precision. Whether they're in the lab or they're working on clinical trials or they're supporting commercial initiatives – they're very mission driven. So how does that help? What does that mean for our clients? It means that they have access to experts who care about their drugs and who understand the need to maximize the value of our clients' investments in our services. What's also important is to minimize the time to market for patients in need. That is very important to our clients and it's very important to our staff. On the commercial side, what we really want to do is bring our expertise to help maximize widespread access for patients who need those treatments.

Hannah: Our CMO, Dr. Harpreet Singh, was the former Division Director of Oncology at the FDA and someone we're incredibly fortunate to have on board now. How has her expertise been helpful in guiding clients through the changes at the Agency?

Margaret Keegan: We're very fortunate our CMO is not only an oncologist, but as you said comes from the FDA. Importantly, she came quite recently in 2024, so her knowledge and expertise are very recent. Again, what does that mean for our clients? It means she can offer real-time advice, and I think what she provides is priceless, particularly right now when companies need to maximize their probability of success and do that through the shortest path to approval possible. You cannot place enough value on that expertise as we navigate these choppy waters with the FDA.

When clients meet Harpreet to talk through the best path for approval and ask about what she's seen with their competitors, what evolves from that is invaluable. After meeting Harpreet, our clients often then meet other experts in the company, like our Chief Scientific Officer or our Head of Clinical Operations. What we're beginning to see is that clients are realizing the benefits of our full breadth of services — we're not just a one-stop small service provider. Starting with Harpreet and all the way across our synergistic services, we are helping guide our clients through these challenging times.

Investor Conference List
May 2025

Healthcare Investor Conferences

Dates	May 2025 Events	Locations
5/7	Wells Fargo Virtual Private Biotech Symposium	Virtual
5/7-5/8	JMP Securities 2025 Life Sciences Conference	New York
5/12-5/14	BioCentury Annual BioEquity Europe	Bruges
5/13	H.C. Wainwright 1st Annual Royalty Company Conference	Virtual
5/13-5/15	BofA 2025 Healthcare Conference	Las Vegas
5/14	Berenberg Diagnostics Conference	London
5/18-5/20	BMO Healthcare Leadership Summit	Santa Fe
5/20	H.C. Wainwright 3rd Annual Bioconnect Investor Conference	New York
5/20-5/21	RBC Capital Markets Global Healthcare Conference	New York
5/20-5/21	Mizuho Neuroscience and Ophthalmology Summit 2025	New York
4/29	Chardan's Trending Issues in Drug Development Conference	Virtual

PRECISION AQ™